In last trading session, Benitec Biopharma Inc (NASDAQ:BNTC) saw 0.56 million shares changing hands with its beta currently measuring 0.83. Company’s recent per share price level of $11.41 trading at -$0.76 or -6.24% at ring of the bell on the day assigns it a market valuation of $264.94M. That closing price of BNTC’s stock is at a discount of -16.48% from its 52-week high price of $13.29 and is indicating a premium of 76.42% from its 52-week low price of $2.69. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 72630.0 shares which gives us an average trading volume of 44.34K if we extend that period to 3-months.
For Benitec Biopharma Inc (BNTC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.14. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.58 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Benitec Biopharma Inc (NASDAQ:BNTC) trade information
Upright in the red during last session for losing -6.24%, in the last five days BNTC remained trading in the red while hitting it’s week-highest on Tuesday, 12/17/24 when the stock touched $11.41 price level, adding 14.15% to its value on the day. Benitec Biopharma Inc’s shares saw a change of 253.25% in year-to-date performance and have moved -3.06% in past 5-day. Benitec Biopharma Inc (NASDAQ:BNTC) showed a performance of 7.04% in past 30-days. Number of shares sold short was 56887.0 shares which calculate 1.35 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 18 to the stock, which implies a rise of 36.61% to its current value. Analysts have been projecting 13 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -13.94% in reaching the projected high whereas dropping to the targeted low would mean a loss of -13.94% for stock’s current value.
Benitec Biopharma Inc (BNTC) estimates and forecasts
Statistics highlight that Benitec Biopharma Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 58.25% of value to its shares in past 6 months, showing an annual growth rate of 40.33% while that of industry is 17.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Benitec Biopharma Inc (NASDAQ:BNTC)’s Major holders
Insiders are in possession of 4.39% of company’s total shares while institution are holding 82.59 percent of that, with stock having share float percentage of 86.38%. Investors also watch the number of corporate investors in a company very closely, which is 82.59% institutions for Benitec Biopharma Inc that are currently holding shares of the company. AWM INVESTMENT COMPANY, INC. is the top institutional holder at BNTC for having 0.62 million shares of worth $4.37 million. And as of 2024-06-30, it was holding 23.9542 of the company’s outstanding shares.
